Description
The ASO achieved broad CNS distribution and reduced CSF DPRs, yet CNS DPRs and pTDP-43 remained abundant with no proteomic changes. This disconnect between peripheral biomarker response and tissue-level pathology challenges current assumptions about ASO efficacy prediction.
Gap type: contradiction Source paper: Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS. (2025, Cell, PMID:40865525)
Resolution criteria
Resolution requires: (1) Pharmacokinetic/pharmacodynamic dissociation experiment: direct intraparenchymal ASO injection into motor cortex or spinal cord of C9orf72 repeat-expansion model (vs. systemic delivery of BIIB078) and quantification of DPR clearance at injection site vs. distal regions, identifying whether failure reflects incomplete CNS distribution, cellular uptake barriers, or turnover rate mismatch; (2) DPR half-life measurement: pulse-chase labeling or ASO washout kinetics in iPSC-derived motor neurons from C9orf72 patients determines DPR (poly-GP, poly-GA) half-life, establishing whether >=6-month treatment duration was insufficient to clear pre-existing aggregate burden (threshold: half-life >90 days would predict insufficient clearance in 6-month trial); (3) Alternative delivery test: intrathecal or intracerebroventricular ASO delivery in C9orf72 mouse model achieves >=70% CNS DPR reduction (vs. 0-20% with BIIB078), and correlates with pTDP-43 reduction >=50%, demonstrating distribution was the limiting factor. Explanations based solely on off-target effects without delivery mechanism data are insufficient.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:25.773096+00:00”, “resolution_summary”: “Resolved by hypothesis h-72c719461c: C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 2, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-72c719461c”, “title”: “C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD”, “score”: 0.378, “reason”: “6 token overlaps; entity overlap: als, aso”, “analysis_id”: “test-hypothesis-fixtures-v1”, “target_gene”: “C9orf72”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“21944792”, “28960178”, “29460270”, “39605053”, “40520109”]}, {“id”: “h-alsmnd-01446b71d93f”, “title”: “MATR3 Nuclear Body Disruption Impairs RNA Processing Hubs and Triggers Splicing Defects in ALS Motor Neurons”, “score”: 0.231, “reason”: “8 token overlaps; entity overlap: als”, “analysis_id”: null, “target_gene”: “MATR3,U1 snRNP,SNRPB,SNRNP70, splicing machinery,spliceosome”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.801172, “confidence_score”: 0.75, “status”: “open”, “pubmed_evidence_ids”: [“20301623”, “24686783”, “30157547”, “35205163”, “38891112”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf_task_9aae8fc5”, “title”: “TDP-43 inclusions occur in AD, ALS, and FTLD but the pathogenic mechanisms leading to TDP-43 pathology may differ between diseases. Understanding disease-specific drivers could reveal why TDP-43 shows limbic distribution in AD versus other patterns in ALS/FTLD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.457, “reason”: “7 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf”, “quality_score”: 0.697, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c_task_9aae8fc5”, “title”: “While the study demonstrates TDP-43 triggers mPTP-mediated mtDNA release, the molecular mechanism by which TDP-43 pathology leads to mPTP opening is not explained. Identifying this upstream trigger could reveal more proximal therapeutic targets than downstream cGAS/STING inhibition.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.433, “reason”: “7 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c”, “quality_score”: 0.772, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046_task_9aae8fc5”, “title”: “While the study establishes TDP-43 triggers mtDNA release via mPTP to activate cGAS/STING, it’s unclear why this pathway preferentially affects motor neurons in ALS when TDP-43 pathology occurs in multiple cell types. Understanding this selectivity is crucial for targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.43, “reason”: “7 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5”, “title”: “The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\n\nGap type: unexplained_observation\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.419, “reason”: “6 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd_task_9aae8fc5”, “title”: “While ALS-causing mutations impair autophagy factors, the neuron-specific effects remain incompletely defined according to the authors. This knowledge gap prevents precise understanding of selective neuronal vulnerability in ALS.\n\nGap type: open_question\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.413, “reason”: “6 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd”, “quality_score”: 0.812, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}